Ulrike Schmid

662 total citations
20 papers, 438 citations indexed

About

Ulrike Schmid is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Ulrike Schmid has authored 20 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 3 papers in Surgery and 3 papers in Molecular Biology. Recurrent topics in Ulrike Schmid's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Medical Imaging and Pathology Studies (3 papers). Ulrike Schmid is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Medical Imaging and Pathology Studies (3 papers). Ulrike Schmid collaborates with scholars based in Germany, United States and United Kingdom. Ulrike Schmid's co-authors include Matthias Freiwald, Claudia Dallinger, Peter Stopfer, Sven Wind, Kristell Marzin, Thomas Ebner, Ralf Lotz, Edeltraut Garbe, Nilesh Patel and M. Jayne Lawrence and has published in prestigious journals such as Journal of Agricultural and Food Chemistry, Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics.

In The Last Decade

Ulrike Schmid

18 papers receiving 429 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulrike Schmid Germany 11 202 64 58 55 52 20 438
Alyce Burke United States 13 88 0.4× 63 1.0× 109 1.9× 50 0.9× 99 1.9× 19 684
Qingqing Cai China 18 70 0.3× 59 0.9× 174 3.0× 140 2.5× 77 1.5× 53 696
Mona Mlika Tunisia 13 212 1.0× 115 1.8× 86 1.5× 22 0.4× 40 0.8× 131 559
Marni Stott‐Miller United States 14 110 0.5× 54 0.8× 162 2.8× 41 0.7× 33 0.6× 24 589
Julien Berthiller France 8 81 0.4× 95 1.5× 94 1.6× 48 0.9× 30 0.6× 8 490
Johanna Schubert United States 8 114 0.6× 69 1.1× 53 0.9× 15 0.3× 26 0.5× 21 429
E. Archier France 10 81 0.4× 89 1.4× 87 1.5× 19 0.3× 46 0.9× 15 739
Giulia Collatuzzo Italy 11 99 0.5× 163 2.5× 68 1.2× 60 1.1× 28 0.5× 49 447
Hirotaka Araki Japan 10 106 0.5× 52 0.8× 111 1.9× 66 1.2× 52 1.0× 26 471

Countries citing papers authored by Ulrike Schmid

Since Specialization
Citations

This map shows the geographic impact of Ulrike Schmid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrike Schmid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrike Schmid more than expected).

Fields of papers citing papers by Ulrike Schmid

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrike Schmid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrike Schmid. The network helps show where Ulrike Schmid may publish in the future.

Co-authorship network of co-authors of Ulrike Schmid

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrike Schmid. A scholar is included among the top collaborators of Ulrike Schmid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrike Schmid. Ulrike Schmid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mendizábal, Nieves Vélez de, Stephan Becker, Gerd Fätkenheuer, et al.. (2024). Semi-mechanistic population pharmacokinetic modeling of DZIF-10c, a neutralizing antibody against SARS-Cov-2: predicting systemic and lung exposure following inhaled and intravenous administration. Journal of Pharmacokinetics and Pharmacodynamics. 52(1). 3–3.
2.
Keller, Sascha, Ulrich Kunz, Ulrike Schmid, et al.. (2024). Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor. Journal of Translational Medicine. 22(1). 934–934. 1 indexed citations
3.
Deterding, Robin R., Matthias Griese, Gail Deutsch, et al.. (2021). Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. ERJ Open Research. 7(2). 805–2020. 15 indexed citations
4.
Schmid, Ulrike, Benjamin Weber, Céline Sarr, & Matthias Freiwald. (2021). Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. BMC Pulmonary Medicine. 21(1). 244–244. 12 indexed citations
5.
Schmid, Ulrike, et al.. (2021). Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. Respiratory Medicine. 180. 106369–106369. 10 indexed citations
6.
Wind, Sven, Ulrike Schmid, Matthias Freiwald, et al.. (2019). Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clinical Pharmacokinetics. 58(9). 1131–1147. 138 indexed citations
7.
Parra‐Guillén, Zinnia P., Ulrike Schmid, Álvaro Janda, Matthias Freiwald, & Iñaki F. Trocóniz. (2019). Model‐Informed Dose Selection for Xentuzumab, a Dual Insulin‐Like Growth Factor‐I/II—Neutralizing Antibody. Clinical Pharmacology & Therapeutics. 107(3). 597–606. 7 indexed citations
8.
Schmid, Ulrike, et al.. (2017). Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis. Cancer Chemotherapy and Pharmacology. 81(1). 89–101. 17 indexed citations
9.
Schmid, Ulrike, et al.. (2017). Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology & Therapeutics. 48. 136–143. 21 indexed citations
10.
Marzin, Kristell, Gunther Kretschmar, Rozsa Schlenker‐Herceg, et al.. (2017). Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment. The Journal of Clinical Pharmacology. 58(3). 357–363. 22 indexed citations
11.
Schmid, Ulrike, Benjamin Weber, Claudia Dallinger, et al.. (2016). Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis. OA4963–OA4963. 2 indexed citations
12.
Freiwald, Matthias, et al.. (2014). Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemotherapy and Pharmacology. 73(4). 759–770. 42 indexed citations
13.
Plag, Jens, Sarah Schumacher, Ulrike Schmid, & Andreas Ströhle. (2013). Baseline and acute changes in the HPA system in patients with anxiety disorders: the current state of research. Neuropsychiatry. 3(1). 45–62. 10 indexed citations
14.
Jobski, Kathrin, et al.. (2012). 3‐year prevalence of alcohol‐related disorders in German patients treated with high‐potency opioids. Pharmacoepidemiology and Drug Safety. 21(10). 1125–1129. 9 indexed citations
15.
Garbe, Edeltraut, Kathrin Jobski, & Ulrike Schmid. (2011). Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Pharmacoepidemiology and Drug Safety. 21(2). 191–198. 21 indexed citations
16.
Garbe, Edeltraut, et al.. (2010). Linkage of mother–baby pairs in the German Pharmacoepidemiological Research Database. Pharmacoepidemiology and Drug Safety. 20(3). 258–264. 42 indexed citations
17.
Patel, Nilesh, Ulrike Schmid, & M. Jayne Lawrence. (2006). Phospholipid-Based Microemulsions Suitable for Use in Foods. Journal of Agricultural and Food Chemistry. 54(20). 7817–7824. 44 indexed citations
18.
Schmid, Ulrike. (2001). Legal Pluralism as a Source of Conflict in Multi-Ethnic Societies. The Journal of Legal Pluralism and Unofficial Law. 33(46). 1–47. 16 indexed citations
19.
Stange, Eduard F., Ulrike Schmid, Wolfgang E. Fleig, & H. Ditschuneit. (1990). [Exclusion diet in Crohn disease: a controlled, randomized study].. PubMed. 28(10). 561–4. 8 indexed citations
20.
Osterwalder, B, et al.. (1987). [Myeloproliferative syndrome and acute febrile neutrophilic dermatosis (Sweet's syndrome)--a rare association].. PubMed. 117(48). 1896–901. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alyce Burke Breakdown of academic impact, for papers by Qingqing Cai Breakdown of academic impact, for papers by Mona Mlika Breakdown of academic impact, for papers by Marni Stott‐Miller Breakdown of academic impact, for papers by Julien Berthiller Breakdown of academic impact, for papers by Johanna Schubert Breakdown of academic impact, for papers by E. Archier Breakdown of academic impact, for papers by Giulia Collatuzzo Breakdown of academic impact, for papers by Hirotaka Araki
Rankless by CCL
2026